Janssen Search
Search results
Late-breaking results from PALOMA-2 study of subcutaneous amivantamab in combination with lazertinib show clinically meaningful antitumor response and improved safety profile in patients with EGFR-mutated non-small cell lung cancer
Jun 03, 2024 Significantly lower infusion-related reactions seen with subcutaneous amivantamab compared with intravenous administration in new Phase 2 data CHICAGO (June 3, 2024) – Johnson & Johnson announced today new data from the Phase 2 PALOMA-2 ...
Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer
Jun 17, 2024 Application based on Phase 3 PALOMA-3 results showing five-fold reduction in infusion-related reactions with five-minute administration of subcutaneous amivantamab Longer overall survival, progression-free survival and duration of response ...
Tom Cavanaugh
TOM CAVANAUGH COMPANY GROUP CHAIRMAN NORTH AMERICA Tom Cavanaugh is Company Group Chairman, North America, Tom is a member of the Innovative Medicine Pharmaceuticals Group Operating Committee and responsible for leading our efforts to transform the health ...
CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy
Apr 06, 2024 United States Expanded indication for this one-time infusion will provide more patients with a potential period away from their multiple myeloma treatment as early as first relapse Approval is based on results from the Phase 3 CARTITUDE-4 ...
Transparency of Clinical Trial Data
Article Type: Clinical Trials Clinical Trial Data Transparency At Janssen, we believe transparency of clinical trial data advances science and medicine and is in the best interest of the patients who use our pharmaceutical products and providers who ...
Our Commitment to Rheumatology
About Rheumatoid Arthritis Rheumatoid arthritis (RA) is a chronic, symmetric, inflammatory disease involving the synovial joints, where bone and cartilage erosion lead to irreversible joint damage. 1 Despite advancements in treatments, 20 to 30 percent of ...
Janssen Aims to Define New Standards of Care in the Treatment of Solid Tumor Cancers with Transformative Data Planned for Presentation at ESMO
Oct 16, 2023 United States Three Phase 3 RYBREVANT ® (amivantamab-vmjw) studies (MARIPOSA, MARIPOSA-2 and PAPILLON) in EGFR-mutated lung cancer achieved statistically significant and clinically meaningful progression-free survival endpoints and will ...
Dan Pettitt
DAN PETTITT VICE PRESIDENT MARKET ACCESS, IMMUNOLOGY Dan Pettitt is Vice President, Market Access, Immunology for the Global Commercial Strategy Organization, Janssen Global Services. He is responsible for developing product access strategies and ...
New Analyses Demonstrate Versatility and Continued Efficacy of TALVEY™ in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Dec 11, 2023 United States Analysis from MonumenTAL-1 study showed patients with relapsed or refractory multiple myeloma treated with TALVEY™ were subsequently treated effectively with several classes of therapy, including CAR-T Additional presentations ...
Finding Value Through the Product Lifecycle
Article Type: Oncology Establishing and Capturing Value Throughout the Product Lifecycle At Janssen, getting our medicines to patients who will benefit is our mission and why we exist. From a market access perspective, this means that, very early in the ...